A Study of TAS1440 With ATRA in Subjects With r/r AML
Public ClinicalTrials.gov record NCT04282668. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of Safety, Pharmacokinetics, and Preliminary Activity of TAS1440, as a Single Agent and in Combination With All-Trans Retinoic Acid (ATRA) in Subjects With Relapsed or Refractory (r/r) Acute Myeloid Leukemia (AML)
Study identification
- NCT ID
- NCT04282668
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Enrollment
- 52 participants
Conditions and interventions
Conditions
Interventions
- TAS1440 Drug
- TAS1440 + ATRA Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 14, 2020
- Primary completion
- Feb 11, 2024
- Completion
- Feb 11, 2024
- Last update posted
- Dec 8, 2024
2020 – 2024
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center Site#127 | Tucson | Arizona | 85719 | — |
| Norton Cancer Institute Site# 108 | Louisville | Kentucky | 40207 | — |
| University of Michigan Medical School Site#107 | Ann Arbor | Michigan | 48109 | — |
| Oregon Health and Science University Site#111 | Portland | Oregon | 97239 | — |
| Fox Chase Cancer Center Site#112 | Philadelphia | Pennsylvania | 19111 | — |
| Baylor Scott & White Research Institute Site#110 | Dallas | Texas | 75246 | — |
| MD Anderson Cancer Center Site#101 | Houston | Texas | 77030 | — |
| Fred Hutchinson Cancer Research Center Site#105 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04282668, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 8, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04282668 live on ClinicalTrials.gov.